1999:HKEXMan Wah Holdings Limited Analysis
Data as of 2026-03-17 - not real-time
HK$4.50
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Man Wah Holdings trades around HK$4.5, comfortably above its 20‑day SMA of ~4.76 but below the 50‑day SMA, indicating a short‑term pullback. The RSI sits near 38, suggesting the stock is not yet oversold, while the MACD histogram is negative, pointing to bearish momentum. Despite a modest revenue decline of about 3%, the company maintains solid gross (≈41%) and operating margins (≈18%) and generates strong operating cash flow exceeding HK$3.4 bn. Valuation metrics are attractive, with a trailing P/E near 8.5 and a P/B of 1.28, well below the sector average, and a dividend yield of roughly 6.7% supported by a payout ratio just over 50%. The DCF model, however, flags a fair value of HK$2.5, implying the market price is premium to intrinsic estimates, yet analyst consensus targets suggest upside of about 24% to HK$5.5.
The stock exhibits low systematic risk (beta ≈0.34) and moderate 30‑day volatility (~35%), but its consumer‑cyclical exposure and heavy reliance on the Chinese market introduce medium sector and geographic risk. Liquidity appears solid with stable trading volumes, and currency risk is moderate given diversified revenue streams. Overall, the fundamentals and dividend profile support a value‑oriented stance, while technical signals caution against immediate upside, leading to a hold recommendation in the short run and a buy outlook for medium to long horizons.
The stock exhibits low systematic risk (beta ≈0.34) and moderate 30‑day volatility (~35%), but its consumer‑cyclical exposure and heavy reliance on the Chinese market introduce medium sector and geographic risk. Liquidity appears solid with stable trading volumes, and currency risk is moderate given diversified revenue streams. Overall, the fundamentals and dividend profile support a value‑oriented stance, while technical signals caution against immediate upside, leading to a hold recommendation in the short run and a buy outlook for medium to long horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram indicating downward momentum
- Price trading below short‑term SMA levels
- RSI near 38 suggesting limited upside in the near term
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst target price around HK$5.5 implies ~24% upside
- Attractive dividend yield with sustainable payout
- Strong cash flow generation supporting earnings growth
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Low beta and stable cash flows provide defensive qualities
- Value‑oriented valuation metrics (low P/E, P/B) suggest upside potential
- Diversified geographic footprint mitigates single‑market concentration
Key Metrics & Analysis
Financial Health
Revenue Growth-3.10%
Profit Margin12.43%
P/E Ratio8.5
ROE15.24%
ROA9.20%
Debt/Equity28.07
P/B Ratio1.3
Op. Cash FlowHK$3.4B
Free Cash FlowHK$721.4M
Technical Analysis
TrendNeutral
RSI38.1
SupportHK$4.45
ResistanceHK$5.20
MA 20HK$4.76
MA 50HK$4.76
MA 200HK$4.60
MACDBearish
VolumeStable
Fear & Greed Index79.45
Valuation
Fair ValueHK$2.49
Target PriceHK$5.60
Upside/Downside24.40%
GradeFair
TypeValue
Dividend Yield6.67%
Risk Assessment
Beta0.34
Volatility34.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.